Gain Therapeutics, Inc.

Clinical/early-stage biotech — clinical-stage biotech micro-cap, funded.

Strengths

• Liquidity — current ratio 6.6 (68th)

Risks

• Pre-revenue, deep losses — per metrics
• Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
• Binary clinical & funding risk — per 10-K

Notable findings

• Chronic dilutionShare count +71%/yr over 4y (dilution, book value/share -94%)
• Notable holderHeld by 2 notable fund(s): STATE STREET CORP, CITADEL ADVISORS LLC (as of 2026-03-31)
• Trial resultTrial topline data reported — see 8-K for outcome 8-K ↗